Inst. Holders
50 funds
DAWN
Day One Biopharmaceuticals, Inc.
—
12-mo target$21.50 (-0.1%)
High Impact Filing (9/10)29 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on DAWN right now — valuation, ownership and activity at a glance.
Inst. Value
$1.2B
Inst. Activity
0 buys / 29 sells
SEC Reports
5
Press Releases
1
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 29, 2026 earnings_calendar
DAWN Q2 2026 Earnings Scheduled — 2026-07-29
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
May 4, 2026 SEC Magnetar Financial LLC — EXIT
0 shares ($0.00)
Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting obligations, effective
15-12G — Impact 5/10
Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective immediately, following the
25-NSE — Impact 9/10
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction valued at $2.5 bill
8-K — Impact 9/10
Apr 23, 2026 Insider
Merendino Lauren disposed of 69,375 shares
Chief Commercial Officer
Apr 23, 2026 Insider
Merendino Lauren disposed of 40,565 shares
Chief Commercial Officer
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Mar 11, 2026 | JP Morgan | DOWNGRADE | Neutral | 55% |
| Mar 10, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Mar 9, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
| Mar 6, 2026 | Jones Trading | DOWNGRADE | Hold | 51% |
| Mar 6, 2026 | Needham | DOWNGRADE | Hold | 50% |
| Feb 25, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Feb 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Feb 25, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jan 13, 2026 | TD Cowen | INITIATE | Buy | 56% |
| Nov 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | 0 | 0 | 10 | 1 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 10 | 1 | 2 | 0% | |
| Jun 1, 2026 | 0 | 0 | 10 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 10 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 10 | 1 | 2 | 0% | |
| Mar 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 4 | 10 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% |
Price targets
Where 6 covering analysts think DAWN trades over the next 12 months.
$21.50 -0.1% upside Hold
Current$21.53 Low$21.50 Median$21.50 High$21.50 6 analysts
$21.50$21.50
Analyst rating None as of Jun 19, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 7.0/10.Plus 1 press releases.
NEUTRAL15-12G5/10
Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting obl
May 4, 2026
NEUTRAL25-NSE9/10
Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective immedia
Apr 23, 2026
NEUTRAL8-K9/10
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction
Apr 23, 2026
NEUTRAL10-K/A4/10
This is an amended 10-K filing by Day One Biopharmaceuticals to include Part II and Part III disclos
Apr 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jul 29, 2026
earnings_calendar
DAWN Q2 2026 Earnings Scheduled — 2026-07-29
Jun 17, 2026
earnings_calendar
DAWN Q1 2026 Earnings Scheduled — 2026-06-17
Jun 5, 2026
earnings_calendar
DAWN Q1 2026 Earnings Scheduled — 2026-06-05
May 1, 2026
earnings_calendar
DAWN Q1 2026 Earnings Scheduled — 2026-05-01
Apr 24, 2026
short_interest
FTD: DAWN — 92,732 shares ($2.0M) failed to deliver
Settlement: 20260424, Price: $21.53, FTD Value: $1,996,519.96, DAY ONE BIOPHARMACEUTICALS INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.17 | $-0.28–$-0.09 | 50.9% | -6.1% | 1↑ 3↓ | $0.1B | 6 |
| Next Q | $-0.16 | $-0.28–$-0.03 | 46.2% | -11.5% | 1↑ 3↓ | $0.1B | 6 |
| Next FY | $-0.04 | $-0.46–$0.35 | 94.3% | -206.0% | 1↑ 3↓ | $0.3B | 6 |
| Current FY | $-0.76 | $-1.76–$-0.16 | 27.4% | -29.5% | 1↑ 5↓ | $0.2B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.172 | — |
| 7d ago | $-0.150 | -0.022 |
| 30d ago | $-0.162 | -0.010 |
| 60d ago | $-0.190 | +0.018 |
| 90d ago | $-0.190 | +0.018 |
Institutional ownership
Which big funds own DAWN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.2B total value (55,406,960 shares) as of 2026-Q1. Top holders: BlackRock,, FIL, VANGUARD. Net buying activity: 15 institutions added/increased vs 6 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,044,487 | $151.0M | 12.9% | EXIT -100.0% |
| FIL Ltd | 4,131,907 | $88.6M | 7.6% | EXIT -100.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,357,684 | $72.0M | 6.1% | EXIT -100.0% |
| JPMORGAN CHASE & CO | 3,134,753 | $67.1M | 5.7% | EXIT -100.0% |
| STATE STREET CORP | 2,869,876 | $61.5M | 5.2% | EXIT -100.0% |
| BALYASNY ASSET MANAGEMENT L.P. | 2,625,235 | $56.3M | 4.8% | EXIT -100.0% |
| UBS Group AG | 2,305,123 | $49.4M | 4.2% | EXIT -100.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,095,813 | $44.9M | 3.8% | EXIT -100.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,954,735 | $41.9M | 3.6% | EXIT -100.0% |
| Qube Research & Technologies Ltd | 1,954,552 | $41.9M | 3.6% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 2,869,876 | 0 | -100.0% | $0.00 |
| Magnetar Financial LLC | EXIT | 645,173 | 0 | -100.0% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | 1,954,735 | 0 | -100.0% | $0.00 |
| JPMORGAN CHASE & CO | EXIT | 3,134,753 | 0 | -100.0% | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | 819,371 | 0 | -100.0% | $0.00 |
| MORGAN STANLEY | EXIT | 687,107 | 0 | -100.0% | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | 1,902,868 | 0 | -100.0% | $0.00 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 1,296,984 | 0 | -100.0% | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | 979,238 | 0 | -100.0% | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 617,561 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | Merendino Lauren | Chief Commercial Officer | D | 69,375 | — | — |
| Apr 23, 2026 | Merendino Lauren | Chief Commercial Officer | D | 40,565 | — | — |
| Apr 23, 2026 | Merendino Lauren | Chief Commercial Officer | D | 25,816 | — | — |
| Apr 23, 2026 | Merendino Lauren | Chief Commercial Officer | D | 110,000 | — | — |
| Apr 23, 2026 | Merendino Lauren | Chief Commercial Officer | D | 90,000 | — | — |
| Apr 23, 2026 | Nicholson Garry A | Director | D | 22,500 | — | — |
| Apr 23, 2026 | Nicholson Garry A | Director | D | 32,335 | — | — |
| Apr 23, 2026 | Nicholson Garry A | Director | D | 37,500 | — | — |
| Apr 23, 2026 | Grossman William | Director | D | 22,500 | — | — |
| Apr 23, 2026 | Grossman William | Director | D | 32,335 | — | — |
All DAWN filing & press-release reports (6)
- 15-12G reportMay 4, 2026
- 25-NSE reportApr 23, 2026
- 8-K reportApr 23, 2026
- 10-K/A reportApr 17, 2026
- PRESS-RELEASE reportMar 6, 2026
- 8-K reportFeb 24, 2026